ELI LILLY AND COMPANY

NYSE: LLY (Eli Lilly and Company)

Last update: 3 hours ago

1,347.11

-4.01 (-0.30%)

Previous Close 1,351.12
Volume 3,540,083
Avg. Volume (3M) 2,579,245
Market Cap 1,199,931,523,072
Price / Earnings (TTM) 43.85
Price / Earnings (Forward) 27.15
Price / Sales 14.32
Price / Book 30.60
52 Weeks Range
850.51 (-36%) — 1,475.25 (9%)
Earnings Date 29 Oct 2026
TTM Dividend Yield 0.50%
Profit Margin 31.90%
Operating Margin (TTM) 51.25%
Diluted EPS (TTM) 30.72
Quarterly Revenue Growth (YOY) 38.60%
Quarterly Earnings Growth (YOY) 15.50%
Total Debt/Equity (MRQ) 122.93%
Current Ratio (MRQ) 1.39
Operating Cash Flow (TTM) 30.65 B
Levered Free Cash Flow (TTM) 9.34 B
Return on Assets (TTM) 21.06%
Return on Equity (TTM) 86.02%

AIStockmoo Score

0.6
Neutral for 3 days
The price implies earnings growth of 21.6% a year; the business can fund about 15.0% a year. info
Cheaper than its usual valuation. info
Earns well above its cost of capital. Returns on capital rising. info
High debt. Strong profitability. Positive cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
Uptrend over the past year. Trading near its 52-week high. info
In an uptrend: the price is above its moving averages, and they are rising. It is close to them. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Recent news mixed or neutral. info
Holdings' Sentiment info NA
Insiders net selling recently. info
Institutions net -16.21% of shares in their latest 13F filings: 2,460 holders increased, 1,979 decreased (quarter to 30 Sep 2026). info
Market environment cautious. info
Sector outperforming the market.
The pillars disagree, so the score is softened.
Priced low for its earnings growth. info
Earnings per share have gone up and down. info
Above its medium-term trend line. info
Price is high against its 52-week average. Up over 5 years. info
Trend up on all three terms. Short-term momentum rising. info
Price is near support. Levels trending down. info
Final Score 0.60
Show all

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Mixed Bullish
Drug Manufacturers - General (Global) Mixed Bullish
Stock Eli Lilly and Company Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
LLY 1 T 0.50% 43.85 30.60 0.6
MRK 327 B 2.44% 128.94 7.57 -0.1
NVS 284 B 3.09% 28.72 7.87 1.7
JNJ 651 B 1.98% 41.04 8.05 0.4
ABBV 506 B 2.44% 49.18 - 0.3
NVO 171 B 29.67% 9.82 5.27 0.0

Select this tab to load the latest available analysis.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Growth
% Held by Insiders 0.19%
% Held by Institutions 85.73%

Ownership

Name Date Shares Held
Lilly Endowment Inc 30 Sep 2026 90,066,978
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
JONSSON PATRIK - 1,432.29 -704 -1,008,332
Aggregate Net Quantity -704
Aggregate Net Value ($) -1,008,332
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 1,432.29
Name Holder Date Type Quantity Price Value ($)
JONSSON PATRIK Officer 10 Nov 2026 Disposed (-) 704 1,432.29 1,008,332

Institutions

Institutional ownership: 94.73%

Positions Holders Shares
Increased 2,460 20,285,278
Decreased 1,979 150,872,918
New 225 5,994,988
Sold out 180 27,961,092

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

13 Positive 8 Negative 27 Neutral
Date Type Details
20 Nov 2026 Yahoo Finance Eli Lilly (LLY) After ObesityWeek Is The Stock Still Undervalued
Eli Lilly (LLY) is back in focus after ObesityWeek 2026, where the company released fresh clinical data on its obesity and sleep apnea pipeline, including EloraTZP, retatrutide and Foundayo. The latest ObesityWeek data arrived in a choppy tape for Eli Lilly. The share price has slipped about 2% in…
20 Nov 2026 Yahoo Finance What Does Eli Lilly Offer That Merck Does Not?
Today's big story: Will 2027 Be A 2022 Repeat For Stocks.
20 Nov 2026 Yahoo Finance AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?
Eli Lilly's revenue is climbing at a pace AbbVie can't match, yet AbbVie trades at a noticeably lower earnings multiple.
20 Nov 2026 Yahoo Finance A $4.7 Billion Fund Just Bought These 3 Stocks
Key TakeawaysKinetic Partners Management, a firm that manages $4. 73 billion, made its three biggest third-quarter additions in Eli Lilly, Microsoft and CoreWeave, its 13F filed Nov.
20 Nov 2026 Yahoo Finance Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects?
Lilly and Pfizer offer contrasting growth stories driven by blockbuster drugs, expanding pipelines and strategic investments.
20 Nov 2026 Yahoo Finance iShares U.S. Healthcare ETF (IYH) Sells $17.4 Million of Eli Lilly on Wednesday
The fund sold $105.9 million of stock and bought nothing, cutting all 99 of its positions.
20 Nov 2026 Yahoo Finance What State Street Health Care SPDR (XLV) Sold: Eli Lilly Leads on Wednesday
The fund sold $335.2 million of stock on Wednesday, Nov. 18, cutting all 60 of its positions and buying nothing.
20 Nov 2026 Yahoo Finance ETFs Are Net Sellers of Eli Lilly (LLY) on Nov. 18
ETFs sold $252.2 million of Eli Lilly (LLY) on Wednesday, with 39 buying and 20 selling.
19 Nov 2026 Yahoo Finance Jefferies Has Wall Street’s Highest Target on Eli Lilly (LLY). Why?
We just published a list of the Morgan Stanley’s Vintage Values 2027: 10 Stocks Analysts See Climbing Further and Eli Lilly (NYSE:LLY) ranked 10th on this list. Bloomberg reported on November 13, 2026, that one bank’s strategists expect the S&P 500 to reach 8,700 within 12 months. They also see…
19 Nov 2026 Yahoo Finance Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance
Sanofi and Regeneron both scored in the rare disease space while Lilly's dealmaking streak continued.
19 Nov 2026 Yahoo Finance Eli Lilly (LLY) – The Only Healthcare Name in Ken Fisher’s Fastest-Growing Top Positions
Eli Lilly and Company (NYSE:LLY) rounds out our list of the Top 10 Stocks to Buy According to Billionaire Ken Fisher at number 10. Ken Fisher has spent more than four decades betting that big, globally dominant companies keep winning, and his latest filing shows he still believes it. Fisher Asset…
19 Nov 2026 Yahoo Finance $1,000 Invested in Eli Lilly 10 Years Ago Would Be Worth a Fortune Today
One molecule turned a diversified drugmaker into a trillion-dollar giant, yet recent buyers have watched shares swing hard even as revenue surged. Does Lilly's next chapter justify today's price, or has the best part already happened?
19 Nov 2026 Yahoo Finance General Medicine Brings its GLP-1 Weight Management Care to LillyDirect
General Medicine, a healthcare store founded by the team behind PillPack and Amazon Pharmacy, today announced that its GLP-1 weight management care is available to customers through LillyDirect, Eli Lilly and Company's digital direct to consumer healthcare platform, as one of the independent care…
19 Nov 2026 Yahoo Finance Sector Rotation Dragged Eli Lilly (LLY) Down in Q3 Despite Intact Momentum
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” Q3 2026 investor letter. The letter can be downloaded here. U.S. equity markets rose modestly in the third quarter, with the S&P 500 gaining 2.30% and the…
19 Nov 2026 Yahoo Finance Eli Lilly Stopped Touting Dose Counts. Should You Worry?
Today's big story: Could Anthropic Stock Fall 25…
19 Nov 2026 Yahoo Finance Amgen (AMGN) Has Advanced MariTide Into Phase 3 Trials
Amgen (NasdaqGS:AMGN) has advanced its obesity drug candidate MariTide into Phase 3 clinical trials, targeting the growing anti-obesity treatment market. The firm is positioning MariTide to compete with existing anti-obesity therapies from established players such as Eli Lilly and Novo Nordisk.…
19 Nov 2026 Yahoo Finance Is Immunology Emerging as Eli Lilly's Next Growth Driver?
Lilly is expanding its immunology franchise through growing drug sales, promising pipeline candidates and strategic acquisitions.
19 Nov 2026 Yahoo Finance Eli Lilly (LLY) Expands Its Oncology Research Platform
Eli Lilly (NYSE: LLY) has agreed to acquire Calytrix Bio to add rare blood cancer programs to its oncology pipeline. The firm also announced a multi-target oncology collaboration with Stipple Bio focused on precision cancer therapies for solid tumors. Together, the Calytrix Bio acquisition and…
19 Nov 2026 Yahoo Finance What State Street Health Care SPDR (XLV) Sold: Eli Lilly Leads on Nov. 17
The fund cut all 60 of its positions, selling $250.1 million of stock, led by Eli Lilly at $42.3 million.
18 Nov 2026 Yahoo Finance Lilly Buying Spree Surpasses $32B
Bloomberg's Madison Muller joins Dani Burger on "Bloomberg Deals." Eli Lilly agreed to buy closely held Calytrix Bio in a deal that could be worth up to $1.5 billion, the latest in the drugmaker's $32 billion wave of acquisitions in 2026 as it builds out its cancer and immunology businesses.
18 Nov 2026 Yahoo Finance Health Canada approves Lilly's Mounjaro® (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
Eli Lilly Canada today announced that Health Canada has issued a Notice of Compliance (NOC) for Mounjaro (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular (CV) events (MACE), including CV death, non-fatal heart attack, or non-fatal…
18 Nov 2026 Yahoo Finance Is Lilly Stock's Winning Streak Skill Or Luck?
Today's big story: Anthropic IPO: Priced For 2031, Or 2036…
18 Nov 2026 Yahoo Finance FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.
18 Nov 2026 Yahoo Finance 48 ETFs Add to Lilly (LLY) Holdings on Nov. 16
ETFs bought $141.8 million of Eli Lilly (LLY) shares on Monday.
17 Nov 2026 Yahoo Finance Eli Lilly Is Up 39% in a Year. Barclays Sees Another 9%
Key TakeawaysBarclays raised its Eli Lilly price target to $1,550 from $1,400 and kept its Overweight rating, with the stock close to a 52-week high. Lilly’s third-quarter revenue rose 39% to $24…
17 Nov 2026 Yahoo Finance Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?
Lilly's revenue growth is turbocharged by its weight-loss pipeline, while Novo's global footprint and far lower valuation raise a tougher question about risk versus reward.
17 Nov 2026 Yahoo Finance Third-Party Vendor Linked to Eli Lilly Is Hit by Data Breach
Lilly found no unauthorized access to its own systems, a person familiar with the matter said. Extortion group n0n claims to hold patient and prescriber data.
17 Nov 2026 Yahoo Finance Positive Trial Results Could Be A Big Moment For Eli Lilly Stock
Eli Lilly used ObesityWeek 2026 to share late-stage data on EloraTZP, retatrutide and Foundayo, showing strong effects on weight, A1C, sleep apnea severity and knee osteoarthritis pain in adults with obesity and related conditions. The breadth of positive findings across multiple organs and…
17 Nov 2026 Yahoo Finance Eli Lilly inks cancer pact worth up to $5.9bn with Stipple Bio
Stipple plans to initiate a Phase I trial for an ADC for solid tumours in early 2027…
17 Nov 2026 Yahoo Finance Cathie Wood and 9 Other Big Funds Bought Eli Lilly Last Quarter, While 18 Sold. Who’s Right?
Key TakeawaysOf 456 big funds that have filed 13Fs for the quarter ended Sept. 30, 10 bought Eli Lilly and 18 sold.
17 Nov 2026 Yahoo Finance A $1.5 Billion Reason Why Eli Lilly Stock Is in Focus
Eli Lilly announces $1.5 billion deal to acquire Calytrix Bio. Here’s what the transaction really means for LLY shares.
17 Nov 2026 Yahoo Finance Lilly agrees to acquire Calytrix Bio for $1.5bn
Calytrix Bio shareholders could receive an upfront payment followed by payouts contingent on reaching clinical and regulatory milestones.
17 Nov 2026 Yahoo Finance Was Eli Lilly Stock's 45% Run Visible Early?
Today's big story: Could Nvidia Stock Fall 50%? Follow The Cash.
16 Nov 2026 Yahoo Finance Lilly Bets Up to $1.5 Billion on Calytrix's Preclinical Antibody
The deal is Lilly's second blood cancer acquisition this year, after Ajax Therapeutics…
16 Nov 2026 Yahoo Finance Eli Lilly Makes $1.5 Billion Move Beyond Weight-Loss Drugs
Calytrix is developing an early-stage antibody treatment for essential thrombocythemia and myelofibrosis.
16 Nov 2026 Yahoo Finance Eli Lilly is trouncing Nvidia — and the weight-loss drug trade is beating AI again
Since its Oct. 6 record, Nvidia has shed more than $1.7 trillion in market value. Eli Lilly has added more than $250 billion over the same stretch, a gain topped only by Apple among the market's biggest stocks.
16 Nov 2026 Yahoo Finance CVS Sees a Possible Break-Even Point for GLP-1s
Drugmakers could gain patients while earning less per prescription.
16 Nov 2026 Yahoo Finance CVS white paper aims to pressure drugmakers to lower GLP-1 prices
GLP-1s would save employers money in the long term if priced at $350 a month or less, the company found. “I would love to see this pressure [drugmakers] to bring down prices to something rational,” CMO Amy Compton-Phillips said.
16 Nov 2026 Yahoo Finance Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035
Lilly's Mounjaro and Zepbound Earn USD 16.1 Billion in One Quarter, Novo's Obesity Sales Rise 22% and Oral GLP-1 Pills Open a New Front: Precedence Research Company Intelligence on Leaders, Pipelines, Investments and DealsOttawa, Nov. 16, 2026 (GLOBE NEWSWIRE) -- The global anti-obesity drugs…
16 Nov 2026 Yahoo Finance Eli Lilly to acquire Calytrix Bio in deal worth up to $1.5 billion
Eli Lilly and Co (NYSE:LLY) has agreed to acquire privately held biotechnology company Calytrix Bio for up to $1.5 billion in cash, expanding its efforts to develop treatments for rare blood disorders and strengthen its presence in haematology. Under the definitive agreement, Calytrix…
16 Nov 2026 Yahoo Finance Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion to Expand Blood Cancer Portfolio
Eli Lilly and Company (NYSE:LLY) has agreed to acquire privately held biotechnology company Calytrix Bio in a cash transaction valued at up to $1. 5 billion, expanding its development portfolio of treatments for rare blood cancers.
16 Nov 2026 Yahoo Finance Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
16 Nov 2026 Yahoo Finance Lilly adds to buyout streak with $1.5B purchase of startup Calytrix
Lilly’s 15th announced company acquisition this year — by far the most in the biopharmaceutical sector — centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms.
16 Nov 2026 Yahoo Finance What Does Eli Lilly (LLY) Reveal At ObesityWeek 2026 About Its Growth Path?
Eli Lilly (NYSE:LLY) released new clinical data at ObesityWeek 2026 on Zepbound, Foundayo, EloraTZP, and retatrutide. The update included late-stage obesity and cardiometabolic results that covered weight loss, metabolic markers, and related chronic conditions. Data presented highlighted efficacy…
16 Nov 2026 Yahoo Finance State Street Health Care SPDR (XLV) Sells Eli Lilly and J&J on Nov. 12
The fund sold $300.3 million of stock, cutting all 60 positions and adding nothing, as its assets stood at $50.56 billion.
16 Nov 2026 Yahoo Finance ETFs Are Net Sellers of Eli Lilly (LLY) on Nov. 12
Eli Lilly (LLY) drew $300.9 million in net ETF selling Thursday.
16 Nov 2026 Yahoo Finance Big-name investors pour $100M into DNA therapeutics developer Seawolf
The startup, which also just disclosed an up to $1.2 billion partnership with Sanofi, is backed by Versant, MPM BioImpact, Eli Lilly and Novartis’ venture arm.
09 Nov 2026 CNBC Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
Lilly plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea in adults with obesity.
02 Oct 2026 CNBC Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
30 Sep 2026 CNBC Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
30 Sep 2026 CNBC People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study 
25 Sep 2026 CNBC Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
21 Sep 2026 CNBC Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
21 Sep 2026 CNBC Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
14 Sep 2026 CNBC Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategy
31 Aug 2026 CNBC Trump strikes new drug pricing deals with nine midsized drugmakers
Show more
TTM Dividend Yield 0.50%
5Y Average Dividend Yield 0.78%
Payout Ratio 21.71%
Ex Date Announcement Date Payment Date Details
14 Feb 2025 09 Dec 2024 10 Mar 2025 1.5 Cash
15 Nov 2024 28 Oct 2024 10 Dec 2024 1.3 Cash
15 Aug 2024 24 Jun 2024 10 Sep 2024 1.3 Cash
15 May 2024 06 May 2024 10 Jun 2024 1.3 Cash
14 Feb 2024 08 Dec 2023 08 Mar 2024 1.3 Cash
14 Nov 2023 01 Nov 2023 08 Dec 2023 1.13 Cash
14 Aug 2023 26 Jun 2023 08 Sep 2023 1.13 Cash
12 May 2023 01 May 2023 09 Jun 2023 1.13 Cash
14 Feb 2023 12 Dec 2022 10 Mar 2023 1.13 Cash
14 Nov 2022 17 Oct 2022 09 Dec 2022 0.98 Cash
12 Aug 2022 27 Jun 2022 09 Sep 2022 0.98 Cash
13 May 2022 02 May 2022 10 Jun 2022 0.98 Cash
14 Feb 2022 13 Dec 2021 10 Mar 2022 0.98 Cash
12 Nov 2021 18 Oct 2021 10 Dec 2021 0.85 Cash
12 Aug 2021 29 Jun 2021 10 Sep 2021 0.85 Cash
13 May 2021 03 May 2021 10 Jun 2021 0.85 Cash
11 Feb 2021 14 Dec 2020 10 Mar 2021 0.85 Cash
12 Nov 2020 19 Oct 2020 10 Dec 2020 0.74 Cash
13 Aug 2020 15 Jul 2020 10 Sep 2020 0.74 Cash
14 May 2020 04 May 2020 10 Jun 2020 0.74 Cash
13 Feb 2020 16 Dec 2019 10 Mar 2020 0.74 Cash
14 Nov 2019 22 Oct 2019 10 Dec 2019 0.645 Cash
14 Aug 2019 20 Jun 2019 10 Sep 2019 0.645 Cash
16 May 2019 07 May 2019 10 Jun 2019 0.645 Cash
14 Feb 2019 19 Dec 2018 08 Mar 2019 0.645 Cash
14 Nov 2018 16 Oct 2018 10 Dec 2018 0.5625 Cash
14 Aug 2018 19 Jun 2018 10 Sep 2018 0.5625 Cash
16 May 2018 07 May 2018 08 Jun 2018 0.5625 Cash
14 Feb 2018 11 Dec 2017 09 Mar 2018 0.5625 Cash
14 Nov 2017 16 Oct 2017 08 Dec 2017 0.52 Cash
11 Aug 2017 19 Jun 2017 08 Sep 2017 0.52 Cash
11 May 2017 01 May 2017 09 Jun 2017 0.52 Cash
13 Feb 2017 12 Dec 2016 10 Mar 2017 0.52 Cash
10 Nov 2016 17 Oct 2016 09 Dec 2016 0.51 Cash
11 Aug 2016 20 Jun 2016 09 Sep 2016 0.51 Cash
11 May 2016 02 May 2016 10 Jun 2016 0.51 Cash
10 Feb 2016 08 Dec 2015 10 Mar 2016 0.51 Cash
10 Nov 2015 19 Oct 2015 10 Dec 2015 0.5 Cash
12 Aug 2015 15 Jun 2015 10 Sep 2015 0.5 Cash
14 May 2015 04 May 2015 10 Jun 2015 0.5 Cash
11 Feb 2015 15 Dec 2014 10 Mar 2015 0.5 Cash
12 Nov 2014 20 Oct 2014 10 Dec 2014 0.49 Cash
13 Aug 2014 16 Jun 2014 10 Sep 2014 0.49 Cash
13 May 2014 05 May 2014 10 Jun 2014 0.49 Cash
12 Feb 2014 16 Dec 2013 10 Mar 2014 0.49 Cash
13 Nov 2013 21 Oct 2013 10 Dec 2013 0.49 Cash
13 Aug 2013 18 Jun 2013 10 Sep 2013 0.49 Cash
14 May 2013 03 May 2013 10 Jun 2013 0.49 Cash
13 Feb 2013 17 Dec 2012 08 Mar 2013 0.49 Cash
13 Nov 2012 15 Oct 2012 10 Dec 2012 0.49 Cash
13 Aug 2012 19 Jun 2012 10 Sep 2012 0.49 Cash
13 Feb 2012 12 Dec 2011 09 Mar 2012 0.49 Cash
10 Nov 2011 17 Oct 2011 09 Dec 2011 0.49 Cash
11 Aug 2011 20 Jun 2011 09 Sep 2011 0.49 Cash
11 May 2011 18 Apr 2011 10 Jun 2011 0.49 Cash
11 Feb 2011 13 Dec 2010 10 Mar 2011 0.49 Cash
10 Nov 2010 18 Oct 2010 10 Dec 2010 0.49 Cash
11 Aug 2010 21 Jun 2010 10 Sep 2010 0.49 Cash
12 May 2010 19 Apr 2010 10 Jun 2010 0.49 Cash
10 Feb 2010 14 Dec 2009 10 Mar 2010 0.49 Cash
10 Nov 2009 19 Oct 2009 10 Dec 2009 0.49 Cash
12 Aug 2009 22 Jun 2009 10 Sep 2009 0.49 Cash
13 May 2009 20 Apr 2009 10 Jun 2009 0.49 Cash
11 Feb 2009 15 Dec 2008 10 Mar 2009 0.49 Cash
12 Nov 2008 20 Oct 2008 10 Dec 2008 0.47 Cash
13 Aug 2008 20 Jun 2008 10 Sep 2008 0.47 Cash
13 Feb 2008 17 Dec 2007 10 Mar 2008 0.47 Cash
13 Nov 2007 15 Oct 2007 10 Dec 2007 0.425 Cash
13 Aug 2007 21 Jun 2007 10 Sep 2007 0.425 Cash
11 May 2007 16 Apr 2007 08 Jun 2007 0.425 Cash
13 Feb 2007 18 Dec 2006 09 Mar 2007 0.425 Cash
13 Nov 2006 16 Oct 2006 08 Dec 2006 0.4 Cash
11 Aug 2006 26 Jun 2006 08 Sep 2006 0.4 Cash
11 May 2006 24 Apr 2006 09 Jun 2006 0.4 Cash
13 Feb 2006 19 Dec 2005 10 Mar 2006 0.4 Cash
10 Nov 2005 17 Oct 2005 09 Dec 2005 0.38 Cash
11 Aug 2005 24 Jun 2005 09 Sep 2005 0.38 Cash
11 May 2005 18 Apr 2005 10 Jun 2005 0.38 Cash
11 Feb 2005 20 Dec 2004 10 Mar 2005 0.38 Cash
10 Nov 2004 18 Oct 2004 10 Dec 2004 0.355 Cash
11 Aug 2004 28 Jun 2004 10 Sep 2004 0.355 Cash
12 May 2004 19 Apr 2004 10 Jun 2004 0.355 Cash
11 Feb 2004 15 Dec 2003 10 Mar 2004 0.355 Cash
12 Nov 2003 20 Oct 2003 10 Dec 2003 0.335 Cash
13 Aug 2003 23 Jun 2003 10 Sep 2003 0.335 Cash
13 May 2003 28 Apr 2003 10 Jun 2003 0.335 Cash
12 Feb 2003 16 Dec 2002 10 Mar 2003 0.335 Cash
13 Nov 2002 21 Oct 2002 10 Dec 2002 0.31 Cash
13 Aug 2002 24 Jun 2002 10 Sep 2002 0.31 Cash
13 May 2002 15 Apr 2002 10 Jun 2002 0.31 Cash
13 Feb 2002 17 Dec 2001 08 Mar 2002 0.31 Cash
13 Nov 2001 15 Oct 2001 10 Dec 2001 0.28 Cash
13 Aug 2001 25 Jun 2001 10 Sep 2001 0.28 Cash
11 May 2001 16 Apr 2001 11 Jun 2001 0.28 Cash
13 Feb 2001 18 Dec 2000 09 Mar 2001 0.28 Cash
13 Nov 2000 16 Oct 2000 11 Dec 2000 0.26 Cash
11 Aug 2000 26 Jun 2000 11 Sep 2000 0.26 Cash
11 May 2000 17 Apr 2000 09 Jun 2000 0.26 Cash
11 Feb 2000 20 Dec 1999 10 Mar 2000 0.26 Cash
10 Nov 1999 18 Oct 1999 10 Dec 1999 0.23 Cash
11 Aug 1999 19 Jul 1999 10 Sep 1999 0.23 Cash
12 May 1999 19 Apr 1999 10 Jun 1999 0.23 Cash
10 Feb 1999 21 Dec 1998 10 Mar 1999 0.23 Cash
10 Nov 1998 20 Oct 1998 10 Dec 1998 0.2 Cash
12 Aug 1998 20 Jul 1998 10 Sep 1998 0.2 Cash
13 May 1998 20 Apr 1998 10 Jun 1998 0.2 Cash
11 Feb 1998 15 Dec 1997 10 Mar 1998 0.2 Cash
12 Nov 1997 15 Sep 1997 10 Dec 1997 0.2 Cash
13 Aug 1997 21 Jul 1997 10 Sep 1997 0.36 Cash
13 May 1997 21 Apr 1997 10 Jun 1997 0.36 Cash
12 Feb 1997 16 Dec 1996 10 Mar 1997 0.36 Cash
13 Nov 1996 21 Oct 1996 10 Dec 1996 0.3425 Cash
13 Aug 1996 15 Jul 1996 10 Sep 1996 0.3425 Cash
13 May 1996 15 Apr 1996 10 Jun 1996 0.3425 Cash
13 Feb 1996 18 Dec 1995 11 Mar 1996 0.3425 Cash
13 Nov 1995 17 Oct 1995 11 Dec 1995 0.685 Cash
11 Aug 1995 17 Jul 1995 11 Sep 1995 0.645 Cash
09 May 1995 17 Apr 1995 12 Jun 1995 0.645 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 1.50 1 0.14
2024 5.20 4 0.67
2023 4.52 4 0.78
2022 3.92 4 1.07
2021 3.40 4 1.23
2020 2.96 4 1.75
2019 2.58 4 1.96
2018 2.25 4 1.94
2017 2.08 4 2.46
2016 2.04 4 2.77
2015 2.00 4 2.37
2014 1.96 4 2.84
2013 1.96 4 3.84
2012 1.47 3 2.98
2011 1.96 4 4.72
2010 1.96 4 5.59
2009 1.96 4 5.49
2008 1.41 3 3.50
2007 1.70 4 3.18
2006 1.60 4 3.07
2005 1.52 4 2.69
2004 1.42 4 2.50
2003 1.34 4 1.91
2002 1.24 4 1.95
2001 1.12 4 1.43
2000 1.04 4 1.12
1999 0.920 4 1.38
1998 0.800 4 0.90
1997 1.28 4 1.84
1996 1.37 4 3.75
1995 1.98 3 7.02
Show more

Technical Setup Medium

Trend order
Slope
Entry
Volume
In an uptrend: the price is above its moving averages, and they are rising. It is close to them.
Nearest support: 1,310.64 – 1,343.79 · strong level
Nearest resistance: 1,439.11 – 1,463.57 · moderate level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria